generic adderall | Teva presents the first generation XR® Adderall capsules in the United States

Teva presents the first generation XR® Adderall capsules in the United States




Jerusalem, Israel, April 2, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that it has begun commercial shipments of generic versions of Shire Pharmaceuticals' Adderall (XR® mixed salts of a single amphetamine entity product). , 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg. Generic Teva Adderall XR® capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

Adderall XR® annual sales are approximately $ 1.5 billion in the United States for the twelve months ended February 28, 2009, based on IMS sales data.

In August 2006, a Teva subsidiary, Barr Pharmaceuticals, Inc. signed a licensing agreement with Shire as part of a patent litigation agreement between the parties. Under this agreement, Shire confers the company's exclusive right to sell a generic version of Adderall XR® capsules for 180 days from the date of the commercial launch.

About Teva
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is a leading generic pharmaceutical company in the world. The company develops, manufactures and markets generic and innovative pharmaceutical products as well as active pharmaceutical ingredients and veterinary pharmaceuticals. Over 80% of Teva's sales are in North America and Europe.

Safe Harbor Declaration pursuant to US law on the reform of disputes over private disputes in 1995:
This version contains forward-looking statements, revealing the trust and expectations of today's management. The statement is based on the beliefs and expectations of current management and involves a number of known and unknown risks and uncertainties that could cause actual results, performance or the achievement of our future differ significantly from the results, performance or results expressed or implied from forward-looking statements to the future. , Important factors that could cause or contribute to such differences include related risks: our ability to successfully develop and commercialize pharmaceuticals In addition, the introduction of generic equivalent that compete, to the extent that we are able to obtain the exclusivity of United States market for generic products our new specification and regulatory changes that may prevent us from using exclusive periods, the potential responsibility for the sale of generic products before a final resolution of the patent litigation, including that relating to generic versions of Neurontin, Lotrel® and Protonix®, the current economic conditions, the competition of companies that are branded under greater pressure to counter generic products, or competitors seeking to delay the introduction of generic products, the effects of competition on our products innovations, in particular Copaxone® sales, the dependence on the effectiveness of our patents. and other protections for innovative products, t impact the consolidation of our distributors and customers, the impact of pharmaceutical regulation and pending legislation that could affect the pharmaceutical industry, our ability to achieve the expected results, despite the efforts of our R & D of innovative products, difficulty predicting the Food and Drug Administration, European Drug Agency and the approval of the other regulatory authorities, the uncertainty surrounding the legislative track and rules for the registration and recognition of products based on biotechnology, the regulatory environment and changes in the political and health structures of the various countries, power outages or delays that could result from the production complex of our products and our global supply chain, our ability to identify with success, consummated and integrate acquisitions, including integration of Barr Pharmaceuticals, Inc., the potential exposure to the claimed product to the extent that it is not covered by insurance, p us Aparan to fluctuations in exchange rates, foreign exchange and interest rates, which operates globally significant which may be negatively affected by terrorism, political instability or economic hostility or is large, our ability to enter into the settlement of patent litigation and intensive supervision by the US government, termination or expiration of government programs and tax benefits, impairment of intangible assets and goodwill, environmental risks, and other factors that are discussed in this report and in our other documents filed with the Securities and Exchange Commission ("SEC").